keyword
MENU ▼
Read by QxMD icon Read
search

Secondary hyperparathyroidism

keyword
https://www.readbyqxmd.com/read/28915142/probe-based-confocal-laser-endomicroscopy-in-metastatic-pulmonary-calcification
#1
Igor Vasilev, Igor Mamenko, Irina Tabanakova, Irina Vikulova, Vera Shevel, Alexey Ushkov, Tatiana Novickaya, Ludmila Archakova, Eugene Sokolovich, Piotr Yablonskii
We report a case of metastatic pulmonary calcification in a patient with chronic renal failure on hemodialysis and secondary hyperparathyroidism. The diagnosis was made by using a probe-based confocal endomicroscopy which showed specific structures in the lung tissue and was proven by a transbronchial lung biopsy. To the best of our knowledge, this is the first reported case of the confocal endomicroscopy findings in a patient with metastatic pulmonary calcification.
September 14, 2017: Journal of Bronchology & Interventional Pulmonology
https://www.readbyqxmd.com/read/28905271/pharmacokinetics-of-a-new-oral-vitamin-d-receptor-activator-2-methylene-19-nor-20s-1%C3%AE-25-dihydroxyvitamin-d3-in-patients-with-chronic-kidney-disease-and-secondary-hyperparathyroidism-on-hemodialysis
#2
Richa Pandey, Julia B Zella, Jinge G Zhu, Lori A Plum, Margaret Clagett-Dame, William J Blaser, Wendy Bedale, Hector F DeLuca, Daniel W Coyne
BACKGROUND: 2-Methylene-19-nor-(20S)-1α,25-dihydroxyvitamin D3 (DP001 or 2MD) is a novel, potent 1α-hydroxylated vitamin D analog that binds to the vitamin D receptor and suppresses parathyroid hormone synthesis and secretion with potential for an improved safety profile compared to existing active vitamin D analogs. The purpose of this study was to evaluate the pharmacokinetics of DP001 given orally after hemodialysis. METHODS: DP001 (550 ng) was given orally to 11 hemodialysis patients with secondary hyperparathyroidism after each dialysis session (3 times/week) for 4 weeks...
September 13, 2017: Drugs in R&D
https://www.readbyqxmd.com/read/28873971/clinical-practice-recommendations-for-treatment-with-active-vitamin-d-analogues-in-children-with-chronic-kidney-disease-stages-2-5-and-on-dialysis
#3
Rukshana Shroff, Mandy Wan, Evi V Nagler, Sevcan Bakkaloglu, Mario Cozzolino, Justine Bacchetta, Alberto Edefonti, Constantinos J Stefanidis, Johan Vande Walle, Gema Ariceta, Günter Klaus, Dieter Haffner, Claus Peter Schmitt
In patients with chronic kidney disease (CKD), renal synthesis of active vitamin D [1,25-dihydroxyvitamin D (1,25(OH)2D)] declines and is associated with hypocalcaemia, secondary hyperparathyroidism and the spectrum of CKD-mineral and bone disorder (MBD). In advanced CKD, active vitamin D analogues, including alfacalcidol, calcitriol and paricalcitol, are routinely administered. There are few studies on the use of vitamin D analogues in children with CKD and on dialysis. It is difficult to define bone-specific outcomes that can guide treatment with active vitamin D analogues in children with CKD-MBD...
July 1, 2017: Nephrology, Dialysis, Transplantation
https://www.readbyqxmd.com/read/28869940/severe-secondary-hyperparathyroidism-in-a-hemodialysis-patient-a-case-report-from-mongolia
#4
Saruultuvshin Adiya, Khurtsbayar Damdinsuren, Chuluuntsetseg Dorj
Secondary hyperparathyroidism (SHPT) occurs in patients with chronic renal failure complicated with renal bone disease and soft tissue/vascular calcification. In dialysis patients with severe SHPT, medical treatment may fail and parathyroidectomy (PTX) is indicated for definitive treatment. Severe hypocalcemia from hungry bone disease or postoperative hypoparathyroidism may occur during the postoperative period. We report here a case of severe SHPT in a hemodialysis patient treated with phosphate binders, calcitriol, and calcimimetics but who still required PTX...
2017: Blood Purification
https://www.readbyqxmd.com/read/28867373/etelcalcetide-amg-416-a-peptide-agonist-of-the-calcium-sensing-receptor-preserved-cortical-bone-structure-and-bone-strength-in-subtotal-nephrectomized-rats-with-established-secondary-hyperparathyroidism
#5
Xiaodong Li, Longchuan Yu, Frank Asuncion, Mario Grisanti, Shawn Alexander, Kelly Hensley, Chun-Ya Han, Qing-Tian Niu, Denise Dwyer, Kelly Villasenor, Marina Stolina, Charles Dean, Michael S Ominsky, Hua Zhu Ke, James E Tomlinson, William G Richards
Sustained elevation of parathyroid hormone (PTH) is catabolic to cortical bone, as evidenced by deterioration in bone structure (cortical porosity), and is a major factor for increased fracture risk in chronic kidney disease (CKD). Etelcalcetide (AMG 416), a novel peptide agonist of the calcium-sensing receptor, reduces PTH levels in subtotal nephrectomized (Nx) rats and in hemodialysis patients with secondary hyperparathyroidism (SHPT) in clinical studies; however, effects of etelcalcetide on bone have not been determined...
September 1, 2017: Bone
https://www.readbyqxmd.com/read/28853301/total-parathyroidectomy-versus-total-parathyroidectomy-with-autotransplantation-for-secondary-hyperparathyroidism-systematic-review-and-meta-analysis
#6
Changjia Li, Liang Lv, Hongqiao Wang, Xufu Wang, Bangxu Yu, Yan Xu, Xiaobin Zhou, Yanbing Zhou
BACKGROUND: Total parathyroidectomy (tPTX) and total parathyroidectomy with autotransplantation (tPTX + AT) are effective and inexpensive treatments for secondary hyperparathyroidism (sHPT), but we do not know which one is the optimal approach. Therefore, we undertook a meta-analysis to compare the safety and efficacy of these two surgical procedures. METHODOLOGY: Studies published in English on PubMed, Embase and the Cochrane Library from inception to 27 September 2016 were searched systematically...
November 2017: Renal Failure
https://www.readbyqxmd.com/read/28846459/calcifediol-to-treat-secondary-hyperparathyroidism-in-patients-with-chronic-kidney-disease
#7
Andrea Galassi, Antonio Bellasi, Paola Ciceri, Francesca Pivari, Ferruccio Conte, Mario Cozzolino
Deranged vitamin D metabolism represents an active trigger of secondary hyperparathyroidism (SHPT) in CKD. Correction of 25(OH)D deficiency by nutritional Vitamin D administration is suggested by KDIGO guidelines, to prevent and treat SHPT in CKD stage G3-G5 and G1T-G5T patients, although with a still inconsistent background. Nutritional vitamin D is available as cholecalciferol, ergocalciferol, or calcifediol. Superiority of calcifediol in increasing 25(OH)D levels has been suggested due to its better bioavailability...
August 28, 2017: Expert Review of Clinical Pharmacology
https://www.readbyqxmd.com/read/28845015/-application-of-carbon-nanoparticles-suspension-injection-in-uremic-patients-with-secondary-hyperparathyroidism-underwent-total-parathyroidectomy-2-case-report-and-literature-review
#8
Qian Liu, Yi Gan, Junhui Wu, Xiaorong Li, Ntchantchou Fossi Paul Cedric
Total parathyroidectomy (PTX) can be used to treat secondary hyperparathyroidism (SHPT) in uremic patients, relieving the patient's osteolytic destruction. Complete resection of bilateral parathyroid glands is key to successful operation. Recently, 2 patients successfully received surgical treatment, in which carbon nanoparticles suspension injection were used. With the help of carbon nanoparticles suspension injection, all of the 4 hyperplastic parathyroid glands were found successfully. The parathyroid hormone(PTH) was significantly decreased after operations and the clinical symptoms were relieved simultaneously...
July 28, 2017: Zhong Nan da Xue Xue Bao. Yi Xue Ban, Journal of Central South University. Medical Sciences
https://www.readbyqxmd.com/read/28843775/parathyroid-hormone-contributes-to-the-down-regulation-of-cytochrome-p450-3a-through-the-camp-pi3k-pkc-pka-nf-%C3%AE%C2%BAb-signaling-pathway-in-secondary-hyperparathyroidism
#9
Hiroshi Watanabe, Ryusei Sugimoto, Komei Ikegami, Yuki Enoki, Tadashi Imafuku, Rui Fujimura, Jing Bi, Kento Nishida, Yoshiaki Sakaguchi, Michiya Murata, Hitoshi Maeda, Kenshiro Hirata, Sachiko Jingami, Yu Ishima, Motoko Tanaka, Kazutaka Matsushita, Hirotaka Komaba, Masafumi Fukagawa, Masaki Otagiri, Toru Maruyama
Chronic kidney disease (CKD), which affects, not only renal clearance, but also non-renal clearance, is accompanied by a decline in renal function. Although it has been suggested that humoral factors, such as uremic toxins that accumulate in the body under CKD conditions, could be involved in the changes associated with non-renal drug clearance, the overall process is not completely understood. In this study, we report on the role of parathyroid hormone (PTH), a middle molecule uremic toxin, on the expression of drug metabolizing or transporting proteins using rats with secondary hyperparathyroidism (SHPT) as models...
August 24, 2017: Biochemical Pharmacology
https://www.readbyqxmd.com/read/28843391/-management-of-bone-and-mineral-metabolism-disorders-before-the-dialysis-stage-remains-still-perfectible-data-from-the-french-phosphorus-and-calcium-survey-photo-graphe
#10
Guillaume Jean, Éric Daugas, Hubert Roth, Tilman Drueke, Jean-Louis Bouchet, Thierry Hannedouche, Gérard London, Denis Fouque
Only limited data is available on the management of the chronic kidney disease-associated bone and mineral metabolism disorder (CKD-MBD) in the pre-dialysis stages of CKD in France. A better knowledge of current management habits could lead to an improvement in the implementation of international recommendations (KDIGO). The 3rd version of the French Phosphorus and Calcium Survey Photo-Graphe (Sanofi) included a cohort of CKD stages 4 and 5 patients, whose aim was to examine the prevalence of CKD-MBD and the quality of its management in patients under the care of 62 nephrologists from over 20 geographical regions in France...
August 23, 2017: Néphrologie & Thérapeutique
https://www.readbyqxmd.com/read/28841848/comparative-efficacy-and-safety-of-paricalcitol-versus-vitamin-d-receptor-activators-for-dialysis-patients-with-secondary-hyperparathyroidism-a-meta-analysis-of-randomized-controlled-trials
#11
Yifeng Xie, Peiling Su, Yifan Sun, Hongsheng Zhang, Rong Zhao, Liang Li, Lanfen Meng
BACKGROUND: Secondary hyperparathyroidism (SHPT) is a severe complication for dialysis patients. Vitamin D receptor activators (VDRAs) are used to treat SHPT, but the comparative efficacy and safety between paricalcitol and other vitamin D receptor activators for management of SHPT in dialysis patients has been unproven. METHODS: We searched PubMed, Embase, and the Cochrane Library for the time period through June 2017 to identify randomized controlled trials that evaluated paricalcitol compared with other VDRAs for treatment of SHPT...
August 25, 2017: BMC Nephrology
https://www.readbyqxmd.com/read/28836058/long-term-effects-of-etelcalcetide-as-intravenous-calcimimetic-therapy-in-hemodialysis-patients-with-secondary-hyperparathyroidism
#12
Takashi Shigematsu, Masafumi Fukagawa, Keitaro Yokoyama, Takashi Akiba, Akifumi Fujii, Motoi Odani, Tadao Akizawa
BACKGROUND: Secondary hyperparathyroidism (SHPT) is a serious major complication in hemodialysis patients with chronic kidney disease. Long-term maintenance of serum phosphate, calcium, and parathyroid hormone (PTH) levels in appropriate ranges in these patients is a major challenge. We investigated the efficacy and safety of long-term treatment with etelcalcetide, a novel intravenous calcimimetic, in Japanese SHPT patients on long-term hemodialysis. METHODS: This study was a multicenter open-label study...
August 23, 2017: Clinical and Experimental Nephrology
https://www.readbyqxmd.com/read/28823005/normocalcaemic-primary-hyperparathyroidism-a-diagnostic-and-therapeutic-algorithm
#13
Joaquín Gómez-Ramírez, Radu Mihai
In recent years, there has been increasing interest in understanding the implications of diagnosing normocalcaemic primary hyperparathyroidism (nPHPT). Many patients hope that nPHPT might explain some of their symptoms, but surgeons hesitate to offer treatment to patients whose calcium levels are normal but whose parathyroid hormone (PTH) levels are elevated in the absence of secondary causes of hyperparathyroidism. This potential new diagnosis is not well understood and may lead to inappropriate investigation and possible unnecessary operations...
August 19, 2017: Langenbeck's Archives of Surgery
https://www.readbyqxmd.com/read/28815282/correction-of-vitamin-d-status-by-calcidiol-pharmacokinetic-profile-safety-and-biochemical-effects-on-bone-and-mineral-metabolism-of-daily-and-weekly-dosage-regimens
#14
S Minisola, L Cianferotti, P Biondi, C Cipriani, C Fossi, F Franceschelli, F Giusti, G Leoncini, J Pepe, H A Bischoff-Ferrari, M L Brandi
RATIONALE: Calcidiol can be employed to correct vitamin D deficiency. MAIN RESULTS: Calcidiol administered at daily and weekly regimens over a period of 3 months was able to successfully raise 25-hydroxyvitamin D levels without altering other markers related to bone and mineral metabolism. SIGNIFICANCE: Calcidiol supplementation is effective and safe. INTRODUCTION: The correction of vitamin D status is necessary to maintain an optimal mineral and skeletal homeostasis...
August 16, 2017: Osteoporosis International
https://www.readbyqxmd.com/read/28814738/identification-of-novel-non-secosteroidal-vitamin-d-receptor-agonists-with-potent-cardioprotective-effects-and%C3%A2-%C3%AF-%C3%AF-devoid-of-hypercalcemia
#15
Santosh A Khedkar, Mohammed A Samad, Sangita Choudhury, Ji Yoo Lee, Dongsheng Zhang, Ravi I Thadhani, S Ananth Karumanchi, Alan C Rigby, Peter M Kang
Vitamin D regulates many biological processes, but its clinical utility is limited by its hypercalcemic effect. Using a virtual screening platform to search novel chemical probes that activate the vitamin D signaling, we report discovery of novel non-steroidal small-molecule compounds that activate the vitamin D receptor (VDR), but are devoid of hypercalcemia. A lead compound (known as VDR 4-1) demonstrated potent transcriptional activities in a VDR reporter gene assay, and significantly ameliorated cardiac hypertrophy in cell culture studies and in animal models...
August 16, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28811539/intraoperative-parathyroid-localization-with-near-infrared-fluorescence-imaging-using-indocyanine-green-during-total-parathyroidectomy-for-secondary-hyperparathyroidism
#16
Le Cui, Yang Gao, Heping Yu, Min Li, Birong Wang, Tao Zhou, Qinggang Hu
The detection of all glands during total parathyroidectomy (TPTX) in secondary hyperparathyroidism (SHPT) patients is often difficult due to their variability in number and location. The objective of this study was to evaluate the feasibility of near-infrared fluorescence (NIRF) imaging using indocyanine green (ICG) for intraoperative parathyroid gland (PTG) localization in SHPT patients. Twenty-nine patients with SHPT were divided into two groups with or without intraoperative NIRF imaging. ICG was administered in patients undergoing intraoperative imaging, and the fluorescence of PTGs was assessed...
August 15, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28808512/a-case-of-hypercalcemia-with-double-pathology
#17
Ahmed Abdalla, Ghassan Bachuwa, Samer Al Hadidi
Hypercalcemia has many causes including primary hyperparathyroidism, malignancy, and other rare etiologies. In most of the cases, hypercalcemia is secondary to one etiology. In this case, we are reporting hypercalcemia with two causes. The initial workup showed primary hyperparathyroidism due to parathyroid adenoma. But because all features were not fully explained by primary hyperparathyroidism, further work-up revealed multiple myeloma. This case represents coexistence of two different diseases, which was rarely reported in the literature previously...
July 2017: Journal of Community Hospital Internal Medicine Perspectives
https://www.readbyqxmd.com/read/28803497/exploring-the-potential-value-of-improved-care-for-secondary-hyperparathyroidism-with-a-novel-calcimimetic-therapy
#18
Björn Stollenwerk, Sergio Iannazzo, Kerry Cooper, Vasily Belozeroff
AIMS: This study explored the use of a value-based pricing approach for the new calcimimetic etelcalcetide indicated for the treatment of secondary hyperparathyroidism (SHPT) in patients receiving hemodialysis. It used the US payer perspective and applied the cost-effectiveness framework. Because etelcalcetide is an intravenous therapy that can be titrated for individual patients, and because its utilization is yet to be assessed in real world settings, a range of plausible doses were estimated for etelcalcetide to define a range of prices...
August 14, 2017: Journal of Medical Economics
https://www.readbyqxmd.com/read/28779382/development-of-severe-hyperparathyroidism-despite-short-term-renal-replacement-therapy
#19
Manabu Okada, Yoshihiro Tominaga, Takahisa Hiramitsu, Toshihiro Ichimori
BACKGROUND: We occasionally experience cases of severe secondary hyperparathyroidism (SHPT) that require parathyroidectomy (PTX) despite undergoing short-term renal replacement therapy (RRT). Because the characteristics of such cases have never been discussed, we aimed to elucidate the pathophysiology of severe SHPT after short-term RRT by retrospectively analyzing clinical data. METHODS: A total of 1013 patients with severe SHPT underwent PTX between January 2007 and April 2016 at Nagoya Daini Red Cross Hospital...
August 4, 2017: World Journal of Surgery
https://www.readbyqxmd.com/read/28776554/thyrotoxicosis-occurring-in-secondary-hyperparathyroidism-patients-undergoing-dialysis-after-total-parathyroidectomy-with-autotransplantation
#20
Zhou Xu, Yu-Tuan Wu, Xin Li, He Wu, Hao-Ran Chen, Yan-Ling Shi, Bilal Arshad, Hong-Yuan Li, Kai-Nan Wu, Ling-Quan Kong
No abstract text is available yet for this article.
August 20, 2017: Chinese Medical Journal
keyword
keyword
1088
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"